New findings by Sri Lankan research scientists highlight the effects of a standardized extract Ceylon Cinnamon on blood sugar

A clinical trial conducted by Sri Lankan researchers has shown that a standardized extract of  Ceylon Cinnamon (Cinnamomum zeylanicum), known as CeyCinnXTM, lowers blood sugar  levels in patients with Type 2 diabetes mellitus (T2DM). 

The study was carried out by researchers from RemediumOne and the Clinical Trials Unit of the  University of Kelaniya, in collaboration with Dr. Dimuthu Muthukuda, Consultant  Endocrinologist at Sri Jayewardenepura General Hospital. Published in PLoS ONE, the trial is  the largest study to date examining the benefits of Ceylon Cinnamon extracts in diabetes  management. 

Key Findings of the Study 

The trial found that participants who consumed a daily dose of the Ceylon Cinnamon extract, CeyCinnXTM, had a reduction in fasting blood sugar over 12 weeks compared to those who did  not receive the supplement. While the extract also showed a potential to lower LDL cholesterol (also known as bad cholesterol), this effect was not statistically significant over 12 weeks. 

The study confirmed that the extract was well tolerated, with no adverse effects reported. These  findings support the medicinal value of compounds found in Ceylon Cinnamon and indicate the  need for further research. 

Implications and Future Research 

Given the increasing burden of diabetes, natural interventions like Ceylon Cinnamon extracts  could offer a safe option for blood sugar management. The researchers emphasize that further  studies are needed to explore the long-term benefits and optimal dosing of such extracts. 

The full study findings are available in PLoS ONE and can be accessed at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317904. 

While the trial was sponsored by SDS Spices (Pvt) Ltd, the company had no role in the study’s  design, data collection, or analysis, ensuring the integrity of the research findings.